Literature DB >> 11119299

Ramifications of HLA class I polymorphism and population genetics for vaccine development.

D V Dawson1, M Ozgur, K Sari, M Ghanayem, D D Kostyu.   

Abstract

HLA polymorphism can complicate the design and development of vaccines, especially those that contain a selected number of epitopes and are directed at pathogens prevalent worldwide. Because of HLA class I restricted antigen recognition and ethnic variation in HLA distribution, such vaccines may not be uniformly effective across populations. We, therefore, considered whether it is possible to assemble a panel of HLA-A and/or HLA-B alleles that would allow the formulation of a single vaccine for a set of Caucasian, Black, or Asian populations. In applying an algorithm to predict levels of favorable response, we identified predominant alleles in 15 representative populations. Approximately 80% of the individuals in one African Black population and five Asian populations were positive for at least one of three HLA-A alleles. Eighty percent coverage was also theoretically possible in five Caucasian populations with only five HLA-A alleles. Four of five Black populations analyzed also required five alleles, but the allelic combinations differed. Our findings suggest that HLA-A alleles may be preferred targets because of the increased heterogeneity at HLA-B, although addition of a single HLA-B allele to a set of HLA-A alleles improved coverage. This approach provides for the identification of combinations of alleles that represent a desired percentage of a population and that could be targeted in designing vaccines. For vaccines with known HLA-restricted epitopes, it allows a prediction of theoretical levels of "responder" and "non-responder" status. Finally, these results might be used in the analysis of protein sequences to identify potential CD8+ T-cell epitopes in populations of interest. Biologic variables that may have further relevance are discussed. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11119299     DOI: 10.1002/1098-2272(200101)20:1<87::AID-GEPI8>3.0.CO;2-R

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  16 in total

1.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Authors:  Andreas Mörner; Marianne Jansson; Evelien M Bunnik; Jørgen Schøller; Robert Vaughan; Yufei Wang; David C Montefiori; Nel Otting; Ronald Bontrop; Lesley A Bergmeier; Mahavir Singh; Richard T Wyatt; Hanneke Schuitemaker; Gunnel Biberfeld; Rigmor Thorstensson; Thomas Lehner
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

2.  Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities.

Authors:  Georg M Lauer; Kei Ouchi; Raymond T Chung; Tam N Nguyen; Cheryl L Day; Deborah R Purkis; Markus Reiser; Arthur Y Kim; Michaela Lucas; Paul Klenerman; Bruce D Walker
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Susceptible and protective HLA class 1 alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population.

Authors:  Ramapraba Appanna; Sasheela Ponnampalavanar; Lucy Lum Chai See; Shamala Devi Sekaran
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

4.  MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles.

Authors:  Guang Lan Zhang; David S DeLuca; Derin B Keskin; Lou Chitkushev; Tanya Zlateva; Ole Lund; Ellis L Reinherz; Vladimir Brusic
Journal:  J Immunol Methods       Date:  2010-12-02       Impact factor: 2.303

5.  Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.

Authors:  Jianming Tang; Shenghui Tang; Elena Lobashevsky; Angela D Myracle; Ulgen Fideli; Grace Aldrovandi; Susan Allen; Rosemary Musonda; Richard A Kaslow
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin.

Authors:  Katherine A Richards; Francisco A Chaves; Frederick R Krafcik; David J Topham; Christopher A Lazarski; Andrea J Sant
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

7.  Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes.

Authors:  Pedro A Reche; Derin B Keskin; Rebecca E Hussey; Petronela Ancuta; Dana Gabuzda; Ellis L Reinherz
Journal:  Med Immunol       Date:  2006-05-18

8.  Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.

Authors:  Shira Weingarten-Gabbay; Susan Klaeger; Siranush Sarkizova; Leah R Pearlman; Da-Yuan Chen; Kathleen M E Gallagher; Matthew R Bauer; Hannah B Taylor; W Augustine Dunn; Christina Tarr; John Sidney; Suzanna Rachimi; Hasahn L Conway; Katelin Katsis; Yuntong Wang; Del Leistritz-Edwards; Melissa R Durkin; Christopher H Tomkins-Tinch; Yaara Finkel; Aharon Nachshon; Matteo Gentili; Keith D Rivera; Isabel P Carulli; Vipheaviny A Chea; Abishek Chandrashekar; Cansu Cimen Bozkus; Mary Carrington; Nina Bhardwaj; Dan H Barouch; Alessandro Sette; Marcela V Maus; Charles M Rice; Karl R Clauser; Derin B Keskin; Daniel C Pregibon; Nir Hacohen; Steven A Carr; Jennifer G Abelin; Mohsan Saeed; Pardis C Sabeti
Journal:  Cell       Date:  2021-06-03       Impact factor: 66.850

9.  Derivation of HLA types from shotgun sequence datasets.

Authors:  René L Warren; Gina Choe; Douglas J Freeman; Mauro Castellarin; Sarah Munro; Richard Moore; Robert A Holt
Journal:  Genome Med       Date:  2012-12-10       Impact factor: 11.117

10.  Predicting population coverage of T-cell epitope-based diagnostics and vaccines.

Authors:  Huynh-Hoa Bui; John Sidney; Kenny Dinh; Scott Southwood; Mark J Newman; Alessandro Sette
Journal:  BMC Bioinformatics       Date:  2006-03-17       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.